Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Cost $0.00
NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer
Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.
Category
  • Breast Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date January 13, 2025
Cost $0.00
NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date January 22, 2025
Cost $0.00

Pages